Trial Profile
A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort Versus Plenadren, in Adrenal Insufficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Hydrocortisone (Primary)
- Indications Adrenal insufficiency
- Focus Proof of concept; Therapeutic Use
- Acronyms The CHAMPAIN Study
- Sponsors Diurnal
- 07 Feb 2024 According to the Neurocrine Biosciences media release, top-line clinical data from this trial is expected in first half of 2024.
- 20 Dec 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 05 Dec 2023 According to the Neurocrine Biosciences media release, Top-line clinical data from this trial is expected in 2024.